TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26135280

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention using a goal-oriented set of case management and counseling techniques to promote self-management.
Number of subjects: 0
Study: 23737390

Group type: EXPERIMENTAL
Intervention: Endeavor Zotarolimus‐eluting stent (E‐ZES)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Other drug-eluting stents (DES)
Number of subjects: 601
Study: 21393114

Group type: EXPERIMENTAL
Intervention: Nutrition education guided by 'Dietary Guidelines for Chinese Residents' for one year
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 272
Study: 19372620

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg or 40 mg
Number of subjects: 130
Study: 16489942

Group type: EXPERIMENTAL
Intervention: Plaque index
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plaque weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Powered toothbrush brushing for 2 min
Number of subjects: 12
Study: 14642699

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10888536

Group type: EXPERIMENTAL
Intervention: 5 cups of black tea per day for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 8869095

Group type: EXPERIMENTAL
Intervention: Empirical vancomycin in addition to ceftazidime or piperacillin-tobramycin
Number of subjects: 897

Group type: COMPARATOR
Intervention: Ceftazidime or piperacillin-tobramycin without vancomycin
Number of subjects: 897
Study: 1824048

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 6785807

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study: 31453915

Group type: EXPERIMENTAL
Intervention: Active stimulation with continuous theta burst stimulation (cTBS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 13
Study: 31111250

Group type: EXPERIMENTAL
Intervention: Reading training (RT) for 6 weeks using sequentially presented text (RSVP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Reading training (RT) for 6 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo training (crossword puzzles)
Number of subjects: 37
Study: 27763785

Group type: EXPERIMENTAL
Intervention: Aromatherapy group (AG) with petitgrain essential oil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG) with neutral oil (almond)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aromatherapy group (AG) and Control group (CG)
Number of subjects: 42
Study: 25888525

Group type: EXPERIMENTAL
Intervention: Albendazole (three monthly treatments for one year, three consecutive days of supervised drug intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo (three monthly treatments for one year, three consecutive days of supervised drug intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0
Study: 25117425

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 μg/week) + Ribavirin (1000/1200 mg/day)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b (1.5 μg/kg/week) + Ribavirin (1000/1200 mg/day)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + Ribavirin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b + Ribavirin
Number of subjects: 212
Study: 22378331

Group type: EXPERIMENTAL
Intervention: Sweet preload (0.35 L fruit juice)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Savory preload (0.35 L tomato juice)
Number of subjects: 15
Study: 25885239

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (1 mg/kg) (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rectal tramadol (1.5‐2 mg/kg, maximum 100 mg) (n=20)
Number of subjects: 40
Study: 17671253

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly intramuscular injections
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P)
Number of subjects: 655
Study: 16225528

Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg once daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg once daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dicyclomine 20 mg four times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12385694

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ertapenem 1.5 g
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g and 1.5 g
Number of subjects: 110
Study: 10233270

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 1 week
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 2 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for an additional 4 weeks (for non-responders)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for an additional 4 weeks (for Microsporum infections)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35
Study: 7479198

Group type: EXPERIMENTAL
Intervention: Ascorbate 4.5 g/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2757905

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vigabatrin (fasting state)
Number of subjects: 8
Study: 4901340

Group type: EXPERIMENTAL
Intervention: Bordetella pertussis vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 0
Study: 30930140

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 28985434

Group type: EXPERIMENTAL
Intervention: Oxytocin administration (24 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26573509

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study: 23733149

Group type: EXPERIMENTAL
Intervention: Clinical trial consideration by oncologists
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Clinical trial offers
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Trial acceptance
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Trial refusal
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Eligibility factors
Number of subjects: 293
Study: 22058105

Group type: EXPERIMENTAL
Intervention: Nurse case manager intervention and automated VTE-risk-assessment tool
Number of subjects: 0
Study: 18423985

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1077
Study: 22097102

Group type: EXPERIMENTAL
Intervention: Listening to a steady beat of 66 beats per minute
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sitting in silence (Control)
Number of subjects: 36
Study: 16005154

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 24
Study: 15384292

Group type: EXPERIMENTAL
Intervention: IAN block plus labial infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IAN block alone (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study: 9648960

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg (2x100 microg) via metered dose inhaler with a spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham challenge with normal saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine/methacholine challenge
Number of subjects: 0
Study: 8024992

Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg twice daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events for both etodolac and naproxen
Number of subjects: 0
Study: 3058613

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) during exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo during exercise
Number of subjects: 11
Study: 11376312

Group type: EXPERIMENTAL
Intervention: Slotted tube stent
Number of subjects: 82

Group type: COMPARATOR
Intervention: Self-expanding stent
Number of subjects: 82
Study: 30531234

Group type: EXPERIMENTAL
Intervention: Lofexidine 2.16 mg/d
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Lofexidine 2.88 mg/d
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 29342248

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 1187
Study: 27677387

Group type: EXPERIMENTAL
Intervention: TIMI risk score
Number of subjects: 2854

Group type: EXPERIMENTAL
Intervention: Constructed predictive model including LVEF and eGFR
Number of subjects: 2854
Study: 25063959

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 46
Study: 22282478

Group type: EXPERIMENTAL
Intervention: Tacrolimus/mycophenolate mofetil
Number of subjects: 82

Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 82
Study: 20104189

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg alone or in association with 12.5 or 25 mg hydrochlorothiazide (HCTZ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg in association with 25 mg HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg in association with 25 mg HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg in association with 25 mg HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Irbesartan +/‐ HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ang II
Number of subjects: 30
Study: 17603140

Group type: EXPERIMENTAL
Intervention: School-based cardiovascular-fitness training program (10 weeks, 3 times/week, 1 hr/session at 60‐80% peak heart rate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 30
Study: 14961168

Group type: EXPERIMENTAL
Intervention: Inogatran (low molecular weight direct thrombin inhibitor)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320
Study: 12458652

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan vs Valsartan
Number of subjects: 0
Study: 9657564

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 25
Study: 7907731

Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to amino acids 31-49 of A-gliadin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to amino acids 202-220 of A-gliadin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: N-terminal peptide, residues 3-21 of A-gliadin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intraduodenal infusion of 1 g of gliadin
Number of subjects: 4
Study: 2532579

Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal sodium diet
Number of subjects: 6
Study: 4566100

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30343857

Group type: EXPERIMENTAL
Intervention: Chlamydia testing intervention (multifaceted, clinic-based including computerized reminders, education package, payments for testing, feedback on testing rates)
Number of subjects: 179355

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 179355
Study: 27892761

Group type: EXPERIMENTAL
Intervention: Stress condition (GSP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stress condition (non-GSP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Control condition (GSP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition (non-GSP)
Number of subjects: 80
Study: 26488613

Group type: EXPERIMENTAL
Intervention: Robuvit® (Quercus robur wood extract)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 61
Study: 23502662

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline nebulization
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% saline nebulization
Number of subjects: 100
Study: 21679485

Group type: EXPERIMENTAL
Intervention: 16 g oligofructose
Number of subjects: 31
Study: 18330657

Group type: EXPERIMENTAL
Intervention: Longo stapled hemorrhoidopexy (SH)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MMH)
Number of subjects: 171
Study: 16581486

Group type: EXPERIMENTAL
Intervention: E/e' ratio greater than 15
Number of subjects: 47

Group type: COMPARATOR
Intervention: E/e' ratio 15 or less
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: E/e' ratio
Number of subjects: 47
Study: 12488121

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SUPPORT
Number of subjects: 78

Group type: COMPARATOR
Intervention: Wait List
Number of subjects: 78
Study: 10393452

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide in phospholipid liposomes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial BPO formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pharmacopoeial BPO formulation
Number of subjects: 20
Study: 8891940

Group type: EXPERIMENTAL
Intervention: Quik Floss
Number of subjects: 30

Group type: COMPARATOR
Intervention: Finger Flossing
Number of subjects: 30
Study: 2049819

Group type: EXPERIMENTAL
Intervention: soft lens lubricants
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline
Number of subjects: 30
Study: 6839799

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (3 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (2.4 g)
Number of subjects: 16
Study: 31025207

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment (Fractional CO2 laser + topical tioconazole 28% nail lacquer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical tioconazole 28% nail lacquer
Number of subjects: 30
Study: 30119694

Group type: EXPERIMENTAL
Intervention: Personalized chronotherapy intervention including individually timed bright light therapy (BLT), bi-weekly tailored physical activity (PA) counseling, and general sleep hygiene education.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist control group (CON)
Number of subjects: 96
Study: 27799661

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Shoulder stabilization exercise
Number of subjects: 38
Study: 25183511

Group type: EXPERIMENTAL
Intervention: Cyclosporine A-based immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of diabetic and normal groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: NODAT group
Number of subjects: 0
Study: 23095790

Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m² administered intravenously on day 1 of a 3-week cycle
Number of subjects: 50
Study: 19095213

Group type: EXPERIMENTAL
Intervention: Telavancin (10 mg/kg IV every 24 hours)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Vancomycin (1 g IV every 12 hours)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 194

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 194
Study: 17947266

Group type: EXPERIMENTAL
Intervention: 2.5% povidone-iodine eye drops (PIED)
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Ophthalmic chloramphenicol (OC)
Number of subjects: 2004
Study: 15829574

Group type: EXPERIMENTAL
Intervention: Systematic monitoring using DAS28
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 384
Study: 12478035

Group type: EXPERIMENTAL
Intervention: BoneSource hydroxyapatite cement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Autologous cancellous bone
Number of subjects: 38
Study: 10636599

Group type: EXPERIMENTAL
Intervention: Prenatal cigarette smoke exposure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 100% O2 challenge
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 15% O2 challenge
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-smoking mothers)
Number of subjects: 31
Study: 8722072

Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intensive therapy (continuous subcutaneous insulin infusion)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 29
Study: 2038782

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 micrograms)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Papaverine (60 mg)
Number of subjects: 54
Study: 6817944

Group type: EXPERIMENTAL
Intervention: 20 mg sodium cromoglycate (SCG) powder delivered by Spinhaler
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg sodium cromoglycate (SCG) delivered by pressurized aerosol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: No pre-treatment
Number of subjects: 16
Study: 28981173

Group type: EXPERIMENTAL
Intervention: Writing reflection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral reflection
Number of subjects: 41
Study: 26667921

Group type: EXPERIMENTAL
Intervention: AIT followed by DIET (E‐then‐D, n=12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AIT concurrent with DIET (E+D, n=12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: AIT without DIET (E CON, n=12)
Number of subjects: 36
Study: 25136791

Group type: EXPERIMENTAL
Intervention: Weekly remote monitoring-driven management
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Remote monitoring-driven management
Number of subjects: 1650
Study: 22392415

Group type: EXPERIMENTAL
Intervention: Risperidone plus Ginkgo T.D. (80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 47
Study: 20819645

Group type: EXPERIMENTAL
Intervention: Transulnar approach (TUA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Transradial approach (TRA)
Number of subjects: 240
Study: 19156094

Group type: EXPERIMENTAL
Intervention: Local ozone therapy combined with low-frequency magnetic fields (ozonomagnetophoresis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wound irrigation with ozone
Number of subjects: 60
Study: 15665884

Group type: COMPARATOR
Intervention: Methadone (mean 106 mg, range 80-160)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 mg sublingual)
Number of subjects: 50
Study: 12773357

Group type: EXPERIMENTAL
Intervention: Unprotected receptive anal sex in the previous 6 months
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Unprotected insertive anal sex in the previous 6 months
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Unprotected anal sex with 1 primary partner or multiple partners
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Drug and alcohol use
Number of subjects: 4295
Study: 10759236

Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 at a dose of 900 microg/m2 twice a week for six months
Number of subjects: 44

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 treatment
Number of subjects: 44
Study: 8707562

Group type: EXPERIMENTAL
Intervention: Vignette of a patient with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vignette of a patient without schizophrenia
Number of subjects: 0
Study: 1401090

Group type: EXPERIMENTAL
Intervention: Revised method of conservative palatoplasty
Number of subjects: 21

Group type: COMPARATOR
Intervention: Perko's mucosal flap operation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wardill's mucoperiosteal flap operation
Number of subjects: 21
Study: 4042540

Group type: EXPERIMENTAL
Intervention: Doppler technique for beat-to-beat measurement of cardiac output
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thermodilution method
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nitrous oxide rebreathing method
Number of subjects: 25
Study: 3556813

Group type: EXPERIMENTAL
Intervention: Mental alerting tasks (four different tasks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive listening (as one of the mental alerting tasks)
Number of subjects: 40
Study: 29406176

Group type: EXPERIMENTAL
Intervention: Normal saline 0.9%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced crystalloid (acetate-buffered)
Number of subjects: 60